🇺🇸 Vaccin GenHevac B Pasteur in United States
8 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 8
Most-reported reactions
- Multiple Sclerosis — 2 reports (25%)
- Antibody Test Positive — 1 report (12.5%)
- Myofascitis — 1 report (12.5%)
- Subarachnoid Haemorrhage — 1 report (12.5%)
- Trismus — 1 report (12.5%)
- Upper Motor Neurone Lesion — 1 report (12.5%)
- Weight Decreased — 1 report (12.5%)
Other Immunology / Infectious Disease approved in United States
Frequently asked questions
Is Vaccin GenHevac B Pasteur approved in United States?
Vaccin GenHevac B Pasteur does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Vaccin GenHevac B Pasteur in United States?
Central Hospital, Nancy, France is the originator. The local marketing authorisation holder may differ — check the official source linked above.